MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and tumor cell killing.
The company also presented data on their PRAME-TCR iNKT therapy, designed to treat PRAME-positive solid tumors without requiring lymphodepletion or HLA-matching. A Phase 2 trial of agenT-797 is currently enrolling patients with advanced gastroesophageal cancer, with results expected in 2025.
MiNK Therapeutics ha presentato nuovi dati al SITC 2024, evidenziando i loro programmi di terapia con cellule iNKT. La loro terapia principale, agenT-797, utilizzata da sola o in combinazione con anti-PD-1, ha dimostrato un controllo durevole della malattia in pazienti pesantemente pretrattati. Quando combinata con engager bispecifici che mirano a MUC16, HER2, Claudin 18.2 e DLL3, ha mostrato un'attivazione migliorata delle cellule T e un uccisione delle cellule tumorali.
La compagnia ha inoltre presentato dati sulla loro terapia PRAME-TCR iNKT, progettata per trattare tumori solidi positivi per PRAME senza richiedere linfodeplezione o abbinamento HLA. Attualmente, è in fase di arruolamento un trial di Fase 2 di agenT-797 per pazienti con cancro gastroesofageo avanzato, con risultati attesi per il 2025.
MiNK Therapeutics presentó nuevos datos en el SITC 2024 mostrando sus programas de terapia con células iNKT. Su terapia principal, agenT-797, sola o combinada con anti-PD-1, demostró un control duradero de la enfermedad en pacientes que habían sido tratados de manera intensiva. Cuando se combina con engagers bispecíficos dirigidos a MUC16, HER2, Claudin 18.2 y DLL3, mostró una activación mejorada de células T y eliminación de células tumorales.
La compañía también presentó datos sobre su terapia PRAME-TCR iNKT, diseñada para tratar tumores sólidos positivos para PRAME sin necesidad de linfodepleción o emparejamiento HLA. Actualmente, está en curso un ensayo de Fase 2 de agenT-797 para pacientes con cáncer gastroesofágico avanzado, con resultados esperados para 2025.
MiNK Therapeutics는 SITC 2024에서 iNKT 세포 치료 프로그램에 대한 새로운 데이터를 발표했습니다. 그들의 주요 치료제인 agenT-797는 단독 또는 anti-PD-1와 병용 시, 고용량 치료를 받은 환자에서 지속적인 질병 조절을 보였습니다. MUC16, HER2, Claudin 18.2 및 DLL3을 표적으로 하는 이중 특이성 조절제와 결합했을 때, T 세포 활성화 및 종양 세포 사멸이 향상되었습니다.
회사 측은 또한 PRAME 양성 고형 종양을 치료하기 위해 설계된 PRAME-TCR iNKT 치료에 대한 데이터를 발표했습니다. 림프감소 또는 HLA 일치를 요구하지 않습니다. 현재 agenT-797의 2상 시험이 진행 중이며, 진행성 식도 위암 환자를 모집하고 있으며 결과는 2025년으로 예상됩니다.
MiNK Therapeutics a présenté de nouvelles données lors de SITC 2024 mettant en avant leurs programmes de thérapie par des cellules iNKT. Leur traitement principal, agenT-797, seul ou en combinaison avec anti-PD-1, a montré un contrôle durable de la maladie chez des patients lourdement prétraités. Lorsqu'il est combiné avec des engageurs bispécifiques ciblant MUC16, HER2, Claudin 18.2 et DLL3, il a montré une activation améliorée des cellules T et une destruction des cellules tumorales.
L'entreprise a également présenté des données sur leur thérapie PRAME-TCR iNKT, conçue pour traiter les tumeurs solides positives pour PRAME sans nécessiter de lymphodéplétion ou de correspondance HLA. Un essai de Phase 2 de l'agenT-797 recrute actuellement des patients atteints de cancer gastro-oesophagien avancé, avec des résultats attendus pour 2025.
MiNK Therapeutics hat auf dem SITC 2024 neue Daten vorgestellt, die ihre iNKT-Zelltherapie-Programme zeigen. Ihre Haupttherapie agenT-797 zeigte allein oder in Kombination mit anti-PD-1 eine dauerhafte Krankheitskontrolle bei stark vorbehandelten Patienten. In Kombination mit bispezifischen Engagern, die auf MUC16, HER2, Claudin 18.2 und DLL3 abzielen, zeigte es eine verbesserte T-Zell-Aktivierung und Tumorzell-Tötung.
Das Unternehmen präsentierte auch Daten zu ihrer PRAME-TCR iNKT-Therapie, die entwickelt wurde, um PRAME-positive solide Tumoren zu behandeln, ohne dass eine Lymphodepletion oder HLA-Anpassung erforderlich ist. Eine Phase-2-Studie zu agenT-797 rekrutiert derzeit Patienten mit fortgeschrittenem gastroösophagealen Krebs, deren Ergebnisse für 2025 erwartet werden.
- AgenT-797 demonstrated durable disease control in majority of heavily pretreated patients
- Successful combination potential with checkpoint inhibitors and bispecific engagers
- Phase 2 trial advancing with innovative five-treatment combination regimen
- PRAME-TCR iNKT shows high specificity in preclinical tumor cell killing studies
- Phase 2 trial results not expected until 2025
- PRAME-TCR iNKT data to preclinical studies
Insights
The preclinical data for MiNK's iNKT cell therapies shows promising potential in addressing major challenges in solid tumor treatment. AgenT-797 demonstrates synergistic effects when combined with checkpoint inhibitors and bispecific engagers, potentially enhancing treatment outcomes for resistant cancers. The PRAME-TCR iNKT platform offers several technical advantages over conventional TCR-T cells, including:
- No requirement for lymphodepletion or HLA-matching
- Reduced risk of heterodimerization
- Potential for off-the-shelf availability
- Enhanced targeting of the tumor microenvironment
However, these are still early-stage results, with Phase 2 trial data for AgenT-797 not expected until 2025. The
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit
PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK’s iNKT cell therapy programs, agenT-797 and PRAME-TCR.
“The data we presented at SITC reflect the potential of iNKT cell therapies to offer meaningful advancements in cancer treatment. AgenT-797 shows important immune modulating effects, enhancing the activity of immune checkpoint inhibitors and bispecific engagers,” said Dr. Marc Van Dijk, CSO at MiNK. “Additionally, our PRAME-TCR iNKT represents a novel and differentiated approach to treat PRAME positive solid tumors. By leveraging iNKT cells’ ability to target the tumor microenvironment without lymphodepletion or HLA-matching, we aim to provide durable, scalable, and accessible solutions for patients with limited treatment options.”
AgenT-797 Combination Boosts Activity of Checkpoint Inhibitors and Bispecific Engagers in Challenging Solid Tumors
- AgenT-797 alone or in combination with anti-PD-1 (nivo or pembro) shows durable disease control in majority of heavily pretreated patients.
- AgenT-797 combined with bispecific engagers targeting antigens such as MUC16, HER2, Claudin 18.2, and DLL3, promote increased T-cell activation, efficient tumor cell killing, and reduced exhaustion and myeloid cell activity.
- Ongoing Clinical Studies: AgenT-797 is advancing in an enrolling Phase 2 trial with an innovative five-treatment combination regimen that includes botensilimab, balstilimab, and standard-of-care chemotherapy. This trial targets 2L+ advanced gastroesophageal cancer patients and is being conducted at Memorial Sloan-Kettering Cancer Center, with results expected in 2025.
PRAME-TCR iNKT Represents a Promising Targeted Therapy for Refractory Solid Tumors
- iNKT cells present an ideal platform for tumor-targeting T cell receptor (TCR) expression due to the absence of conventional αβ TCRs and endogenous class I MHC molecules.
- MiNK’s allogeneic PRAME-targeted TCR addresses the limitations of traditional T cell therapies. As an allogeneic, gene-editing-free solution, it expresses an engineered αβ PRAME-TCR with no risk of heterodimerization, offering a potentially safer and more precise approach.
- In preclinical studies, PRAME-TCR-iNKTs direct tumor cell killing with high specificity, which highlights the versatility of iNKT cells and their potential of to treat solid tumors such as NSCLC, ovarian, melanoma and sarcoma.
Presentation Details
Title: AgenT-797 iNKT cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and bi-specific engagers to improve the anti-tumor response
Abstract Number: 753
Date: Friday, November 8th
Title: PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME
Abstract Number: 374
Session Date: Saturday, November 9th
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
What were the key findings for MiNK Therapeutics (INKT) at SITC 2024?
When will MiNK Therapeutics (INKT) release Phase 2 trial results for agenT-797?
What cancers can MiNK Therapeutics' (INKT) PRAME-TCR iNKT potentially treat?
